The novel coronavirus disease 2019 (COVID19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The lack of targeted molecular therapy for patients with SARS-CoV-2 infection has led to high mortality.1 The study of pre-existing cross-reacting immunity to pre- and postpandemic coronaviruses provides direction for the development of targeted molecular therapy for members of this class of virus.2–6 Combining two or more anti-SARS-CoV-2 spike receptor binding domain (RBD) antibodies should strengthen SARS-CoV-2 neutralization and might restrict the generation of neutralization-evading mutants.